S3661 A Blurry Surprise: A Case of Metastatic Melanoma

A Comprehensive Review of Various Therapeutic Strategies for the Management of Skin Cancer

“… 13 Due to difficulties with NMSC identification and documentation, the final figure could be significantly underestimated. 22 The elevated skin tumor rate of death is primarily due to delayed diagnosis, which is triggered by nonspecific symptoms, 23 lack of reliable screening techniques, 24 a lack of precise and sensitive biomarkers for prompt detection, prognosis, and therapy monitoring, 25 and a lack of knowledge of the mechanisms underlying resistance to drugs in these tumors. 26 Therefore, over the past two years, the COVID-19 pandemic, which has taken a lead role in everyday clinical practice, has limited the availability of medical services and delayed the detection of individuals with CM and other skin tumors, leading to higher rates of illness and death, and as a consequence, more financial strain on medical facilities.…”

Skin Cancer Research Goes Digital: Looking for Biomarkers within the Droplets

“…However, the latter might be a gross underestimation of the real number, due to challenges related to NMSC diagnosis and reporting [ 6 ]. The increased rate of fatality in skin cancer is mainly attributed to late diagnosis, due to non-specific symptoms [ 7 , 8 ], the absence of effective screening methods [ 9 ], the lack of sensitive and specific biomarkers for early diagnosis, prognosis, and treatment follow-up [ 10 ], as well as to a limited understanding of drug resistance mechanisms in these tumors [ 11 ]. Hence, in the last two years, the COVID-19 pandemic, which has become the epicenter of daily clinical practice, restricted access to healthcare facilities and delayed the diagnosis of patients with CM and other skin cancers, resulting in increased rates of morbidity, mortality, and, consequently, a greater financial burden on the health system [ 12 ].…”